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BACKGROUND: Low anterior resection syndrome is 
pragmatically defined as disordered bowel function after 
rectal resection leading to a detriment in quality of life. 
This broad characterization does not allow for precise 
estimates of prevalence. The low anterior resection 
syndrome score was designed as a simple tool for clinical 
evaluation of low anterior resection syndrome. Although 
the low anterior resection syndrome score has good 
clinical utility, it may not capture all important aspects 
that patients may experience.
OBJECTIVE: The aim of this collaboration was to develop 
an international consensus definition of low anterior 
resection syndrome that encompasses all aspects of the 
condition and is informed by all stakeholders.
DESIGN: This international patient-provider initiative 
used an online Delphi survey, regional patient consultation 
meetings, and an international consensus meeting.
PARTICIPANTS: Three expert groups participated: 
patients, surgeons, and other health professionals from  
CONSENSUS STATEMENT
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5 regions (Australasia, Denmark, Spain, Great Britain and 
Ireland, and North America) and in 3 languages (English, 
Spanish, and Danish).
MAIN OUTCOME MEASURE: The primary outcome 
measured was the priorities for the definition of low 
anterior resection syndrome.
RESULTS: Three hundred twenty-five participants (156 
patients) registered. The response rates for successive 
rounds of the Delphi survey were 86%, 96%, and 99%. 
Eighteen priorities emerged from the Delphi survey. 
Patient consultation and consensus meetings refined 
these priorities to 8 symptoms and 8 consequences that 
capture essential aspects of the syndrome.
LIMITATIONS: Sampling bias may have been present, 
in particular, in the patient panel because social media 
was used extensively in recruitment. There was also 
dominance of the surgical panel at the final consensus 
meeting despite attempts to mitigate this.
CONCLUSIONS: This is the first definition of low anterior 
resection syndrome developed with direct input from 
a large international patient panel. The involvement of 
patients in all phases has ensured that the definition 
presented encompasses the vital aspects of the patient 
experience of low anterior resection syndrome. The 
novel separation of symptoms and consequences may 
enable greater sensitivity to detect changes in low anterior 
resection syndrome over time and with intervention.
KEY WORDS: Consensus definition; Low anterior 
resection syndrome; Patient reported; Rectal resection.
Internationally, colorectal cancer is the third most com-mon cancer with 1.8 million cases reported in 2018.1 The introduction of stapling devices and other tech-
niques has facilitated a rise in sphincter-saving surgery for 
rectal cancer.2 Total mesorectal excision and radiotherapy 
have dramatically improved oncological outcomes.3,4 Im-
proved survival has heightened awareness of survivorship 
issues, including bowel dysfunction.5 Consequently, cli-
nicians and researchers have been urged to look beyond 
survival and recurrence as the sole measures of treatment 
success.6 Core outcomes sets that specify a minimum set 
of outcomes to be measured have been proposed to reduce 
the heterogeneity of outcome reporting and reporting bias 
in clinical trials.7 The proposed core outcomes set for colo-
rectal cancer surgery includes quality of life and functional 
outcomes, highlighting the importance of these outcomes.7
The term low anterior resection syndrome (LARS) 
describes “disordered bowel function after rectal resec-
tion, leading to a detriment in quality of life.”8 Although 
pragmatic, this definition can incorporate a vast array of 
symptoms from fecal incontinence and urgency, to evac-
uation difficulties. Consequent heterogeneity in reporting 
makes it impossible to accurately identify the prevalence of 
LARS.9–11 Development of a validated patient-reported out-
come measure, the LARS score, has improved the standard-
ization of reporting.12 Prevalence of LARS using this tool 
is reported to be 41% (95% CI, 34%–48%).13 The LARS 
score has good psychometric properties and has been vali-
dated in multiple languages.14–17 However, the LARS score 
may significantly underestimate the impact of evacuatory 
dysfunction and may not accurately assess the impact of 
symptoms on an individual patient’s quality of life.18
Like most patient-reported outcome measures, the LARS 
score was initially produced by expert clinician researchers 
who then consulted patient populations.12 Active involve-
ment of all major stakeholders, especially patients, early in the 
construction of any outcome measure is necessary to ensure 
that the resulting tool is fit for purpose, as outlined by the 
COMET19 and COSMIN20 guidelines. The aim of this study is 
to use an international patient-provider initiative with robust 
methodology to produce a consensus definition of LARS. 
This is the first phase of a wider project to construct a tool to 
accurately identify survivors who have LARS, assess severity, 
and enable evaluation of treatment approaches.
MATERIALS AND METHODS
Scientific Committee
A Scientific Committee of patients and clinicians was 
convened to oversee the study. Clinician representatives 
were also lead investigators for each region involved in the 
study: Australasia, Denmark, North America, Spain, Great 
Britain and Ireland. Two patient representatives formed 
part of the Scientific Committee and contributed directly 
to conception, methodology, recruitment, interpreta-
tion, and presentation of results. Ethical approval for this 
study was granted by the University of Auckland Human 
Participants Ethics Committee (Ref 019179).
Participants
Three groups of experts were enrolled in this study: patients 
(panel A), surgeons (panel B), and other health care pro-
fessionals (panel C). There is no agreed method of de-
termining required sample size for a consensus method 
Delphi survey,21 so a minimum recruitment target was set 
to balance the need for breadth of opinion and interna-
tional involvement with resources available. Recruitment 
target was 120 patients (24 per region), 60 surgeons, and 
60 other health care professionals (12 of each per region). 
Regional lead investigators were responsible for recruitment 
in their region. Maximum diversity sampling (nonproba-
bilistic purposeful sampling) was used to recruit a wide 
range of perspectives. The study was advertised via social 
media through charitable colorectal cancer organizations 
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and peer support groups. Patient participants could volun-
teer by registering online. Care was taken to enroll patient 
participants who did not have a clinician-patient relation-
ship with lead investigators. All participants completed an 
enrollment registration form to obtain demographic details 
and, for patients, eligibility criteria and treatment informa-
tion. Participants who completed a registration form were 
deemed to have given their consent to participate in the 
study; an additional consent form was not required.
Panel A
Patients were eligible to participate if they had undergone 
an anterior resection for rectal cancer more than 12 months 
earlier with or without diverting ileostomy, providing any 
ileostomy had then been closed for at least 6 months and 
that adjuvant treatment had been completed. Patients who 
did not meet the inclusion criteria, who were receiving on-
going treatment for recurrent or metastatic disease, or who 
had cognitive impairment, were excluded. Poor bowel func-
tion was not a requirement for eligibility; patients with 
good bowel function were also encouraged to participate.
Panel B
Surgeons were recruited via lead investigators in con-
sultation with relevant societies: Association of 
Coloproctology of Great Britain and Ireland (ACPGBI), 
Royal Society of Medicine Section of Coloproctology 
(RSM Coloproctology), Colorectal Surgical Society of 
Australia and New Zealand (CSSANZ), Colon and Rectal 
Surgery Section of Royal Australasian College of Surgeons 
(RACS), European Society of Coloproctology (ESCP), and 
American Society of Colon and Rectal Surgeons (ASCRS).
Panel C
Other specialists who treat or conduct research into LARS 
were identified by lead investigators and invited to par-
ticipate. This panel included specialist nurses, biofeedback 
specialists, physiotherapists, gastroenterologists, oncolo-
gists with special interest in functional outcome after 
rectal cancer treatment, and pelvic floor specialists with 
an interest in managing LARS.
Longlisting of Potential Outcomes
Systematic review of literature published between 1986 and 
2016 that reported functional outcomes after sphincter-pre-
serving rectal resection was undertaken to produce a com-
prehensive list of bowel function outcomes that were then 
tested in a pilot study. The results of this review have been 
published9 and were used in round 1 of the Delphi survey. 
Participants were invited to add novel items during round 1.
Phase 1: Online Delphi Survey
Delphi methodology aims to produce a conver-
gence of opinion using multiple iterative rounds of a 
questionnaire.22,23 The Delphi survey consisted of 3 rounds, 
available to participants in 3 languages: Danish, English, 
and Spanish. The first round was sent to all eligible regis-
tered participants; patients, health care professionals, and 
surgeons. Subsequent rounds were only sent to participants 
who completed the previous round and were accompa-
nied by a graphical summary of how each expert group 
responded to each question (“item”) in the previous round 
(See Appendix A, http://links.lww.com/DCR/B127). Survey 
Monkey platform was used to manage surveys. Patient rep-
resentatives sent newsletters to maintain participant en-
gagement and highlight focus on patient perspective.
In each survey, participants were asked to rank each 
item on a 1 to 9 point Likert scale from Not Important (1) to 
Essential (9) for the definition of LARS, with an additional 
response option Unable to comment (0) (see Appendix A for 
the format of a question, http://links.lww.com/DCR/B127). 
Likert rankings of 7 to 9 in any round were considered to in-
dicate high-priority items, ratings of 4 to 6 indicated mod-
erate-priority items that were important but not critical 
for the definition, and rankings of 1to 3 were low priority. 
The Scientific Committee applied a priori decision rules to 
determine which items progressed to the next round (see 
Appendix B, http://links.lww.com/DCR/B128). During the 
first round, participants were invited to provide additional 
items important for the definition of LARS. Thematic anal-
ysis of all additional items was undertaken and these items 
were included in round 2 (see Appendix C for questions 
included in each round, http://links.lww.com/DCR/B129). 
Round 3 incorporated items that met consensus criteria for 
“high priority” in round 1 or round 2 and items that had 
not met consensus in round 2.
Phase 2: Patient Consultation Meetings
Each region convened a patient consultation meeting to elicit 
detailed information on patient views by using the nominal 
group technique.24 A uniform template of phase 1 results was 
prepared, and the discussion was centered around items that 
had not met consensus in the Delphi survey. The meetings 
allowed discussion of items that may have been misrepre-
sented or divided votes due to overlap. Face-to-face meetings 
were held in London, Barcelona, and Aarhus. Because of ge-
ographical constraints, 2-hour teleconference meetings were 
held for Australasian and North American patient expert 
panels using the Zoom web-based conferencing platform. 
Online meetings were recorded and transcribed.
Phase 3: Consensus Meeting
Participants who completed all 3 Delphi survey rounds 
were invited to attend the international multidiscipli-
nary consensus meeting held in Nice, France, at the 2018 
Annual ESCP meeting. Feedback from all patient consul-
tation meetings was presented before discussion to achieve 
final consensus. Polling was used to assess whether items 
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that had met “high priority” consensus during the Delphi 
survey were required for the definition and to determine 
whether related items could be amalgamated.
Data Analysis
Descriptive statistics including percentages and median 
(range) are presented. The χ2 test was used for compari-
sons between categorical data. Correlations were assessed 
using the nonparametric Spearman rho (ρ) test. IBM SPSS 
Statistics for Macintosh Version 24.0 and GraphPad Prism 
v.7 for Mac OS X (GraphPad Software, La Jolla, CA) were 
used for the statistical analyses.
RESULTS
The study methodology and number of participants at 
each stage are summarized in Figure 1.
Participants
Three hundred twenty-five participants registered: 156 
patients, 96 colorectal surgeons, and 73 health care profes-
sionals; 55 from Australasia, 53 from Denmark, 44 from 
Spain, 93 from Great Britain and Ireland, and 80 from 
North America. Details of participants registered for each 
expert panel are shown in Table 1. Participants complet-
ing each Delphi survey round were invited to participate 
in the next rounds, so the response rate denominator is 
the number of participants in the previous round. Overall 
response rates were 86% (278/325) for round 1, 96% 
(268/278) for round 2, and 99% (265/268) for round 3. 
Response rates for each region and expert panel are shown 
in Figure 2.
Delphi Survey
Round 1 contained 37 items. The patient panel produced 
the most discriminatory rankings, but overall group and 
patient panel rankings were similar. Eight items were 
ranked “high priority” (scores of 7–9 out of 9) by the ma-
jority (67%) of all 3 panels and a further 5 items were 
ranked “high priority” by the majority (67%) of the pa-
tient participants, so these items progressed directly to 
round 3. Incontinence (of any kind): unintended passage of 
solid, liquid or gaseous fecal material was removed because 
it was redundant (the responses to this were highly cor-
related with the responses to the questions regarding solid 
stool incontinence (ρ = 0.84) and liquid fecal incontinence 
(ρ = 0.88)). Two items that met the criterion for high pri-
ority were amalgamated to reduce splitting of the vote be-
tween related items (ρ = 0.59): Stool frequency: number of 
bowel movements per 24 hours and Stool frequency >4 per 24 
hours. No items in round 1 met the consensus criterion for 
“low priority”; therefore, all other items were represented 
in round 2 for further consideration (see Appendices C 
and D, http://links.lww.com/DCR/B129 and http://links.
lww.com/DCR/B130).
Round 2 included 24 items that did not meet con-
sensus in round 1 and 15 new items generated by both 
patients and clinicians from round 1. The patient panel 
again produced the most discriminatory rankings. 
Patient representatives on the steering group raised con-
cerns that certain items were being ranked lower because 
of wording issues and split voting. The steering group 
recognized that patients were less likely than clinicians 
to discard important symptoms and so the majority cri-
terion was lowered from 67% to 55% to ensure impor-
tant items were not lost before the final round of voting. 
Eighteen items progressed to round 3 based on the cri-
teria that the majority (55%) of patient panelists ranked 
an item as high priority and less than 33% of panelists 
ranked it as a low-priority item.
Round 3 included 29 items: 11 from round 1 and 
18 items from round 2. Two items were reworded based 
on survey feedback and advice from patient representa-
tives. Inability to cope with bowel function was reworded 
to need to use coping strategies to manage bowel function. 
Effect on sexual function was reworded to impact on sexu-
ality and sexual life. A discernible cutoff point was evident 
above which the proportion of participants giving a high-
priority ranking sharply increased, and the proportion of 
participants giving a low- or moderate-priority ranking 
sharply decreased. This cutoff point (majority of 70%) was 
the criterion on which all items were assessed for inclusion 
in round 3. Appendix E, http://links.lww.com/DCR/B131, 
shows expert panel and overall rankings for all items.
Eighteen items met consensus criteria: clustering/
fragmentation, incomplete emptying, difficulty empty-
ing, stool frequency, soiling, fecal incontinence, urgency, 
inability to defer defecation, variable/unpredictable bowel 
function, dissatisfaction with bowel function, preoccupa-
tion with bowel function, toilet dependence, need to use 
coping strategies to manage bowel function, fear and/or 
anxiety over bowel control, effect on quality of life, effect 
on overall well-being, effect on lifestyle/daily activities, 
and effect on social activities.
Patient Consultation Meetings
In total, 42 patients participated in 5 meetings. Carers also 
attended and contributed. One important concept iden-
tified as missing was effect on mental health/psychological 
consequences of changes in bowel function. There was ge-
neral agreement that pain related to defecation or to the 
urge to defecate was important despite variable interpre-
tations of tenesmus. There was agreement that impact on 
sexuality and sexual life and effect on ability to perform 
usual work are very important but needed rewording. 
Patients suggested expanding effect on ability to perform 
usual work to include roles within family, community, 
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and other organizations, not just paid employment. There 
was agreement that the impact of LARS on sexuality was 
not solely due to changes in sexual function, but related 
more broadly to the impact on intimacy. Change in stool 
consistency was considered important, but diarrhea was 
mostly inevitable and was not itself the problem, whereas 
unpredictability of bowel movements and paste-like stool 
consistency made it difficult to evacuate. There was general 
agreement that some items may be amalgamated because 
they represented similar underlying concepts.
Final Consensus Meeting
Thirty-five Delphi participants attended the facilitated 
consensus meeting (Fig. 3). Discussion was structured 
around items that had met consensus but had potential to 
be amalgamated and items for which there were significant 
35 items from review
1 item from the pilot
Literature review
pilot study
Participant recruitment
Online Delphi survey
Patient consultation meetings
Consensus Meetings
Consensus Statement
Patient panel n = 156
Health professional panel n = 73
Surgeon panel n = 96
Round 1 – 37 items
Overall response rate 86%
Patients 123, healthcare professionals 63, surgeons 92
Round 2 – 39 items
Overall response rate 96%
Patients 114, healthcare professionals 63, surgeons 91
Round 3 – 29 items
Overall response rate 99%
Patients 111, healthcare professionals 63, surgeons 91
Meetings in London (10 patients), Aarhus (9 patients),
  Barcelona (12 patients), Australasia (7 patients
online) and North America (7 patients online).
Face-to-face meetings in Nice, France, 35 Attendees:
Patients 6, healthcare professionals 7, surgeons 22
FIGURE 1. Study methodology.
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discrepancies in ranking among groups. Real-time elec-
tronic polling was used to identify whether a consensus 
had been reached after discussion of each item. The crite-
rion for consensus was 70% of attendees.
Visual aids were used to ensure that patient voice was pre-
sent during the meeting, including continuous PowerPoint 
presentation of patient participant quotes as well as post-
ers of statements from patient participants during previous 
phases. The meeting opened with presentations from each 
regional lead investigator summarizing the patient consulta-
tion meetings. During group discussion of each item, patient 
representatives were invited to articulate the patient voice.
Consensus meeting discussion clarified that symp-
toms should be differentiated from impact or con-
sequences of LARS. Figure 4 describes outcomes 
throughout each phase of the study (details in Appendix 
F, http://links.lww.com/DCR/B132). Eight symptom 
complexes and 8 consequences were agreed on as the 
most important priorities for definition of LARS (Fig. 5). 
To meet the definition of LARS, a patient must have had 
an anterior resection (sphincter-preserving rectal resec-
tion) and have at least 1 of these symptoms that results 
in at least 1 of these consequences. Increased stool fre-
quency was compared to preoperative stool frequency. 
Repeated painful stools includes pain on urge, on passing 
a bowel movement, and/or after passing a bowel move-
ment. Emptying difficulties include difficulty emptying 
the bowel for any reason, a feeling that the bowel has not 
completely emptied after passing a bowel movement, and 
need to return to the toilet multiple times to empty the 
bowel. Fecal incontinence is defined as the unintended 
passage of a large volume of fecal material. Fecal urgency 
is the need to rush to the toilet to defecate and/or the in-
ability to delay passing a bowel movement. Soiling is the 
involuntary passage of a small amount of material onto 
clothing or sanitary item.
Patient Australasia Denmark
10
20
30
40
50
60
70
80
90
100
Response rate (%)
Round 2Round 1 Round 3
Spain
Regional response rate
UK USAHealthcare
professionals
Surgeon
Expert panel response rate
FIGURE 2. Response rate for each group. Round 1 (left, blue bar) to round 3 (right, green bar). The response rate is given as a percentage 
above each bar (the denominator for the response rate calculation is the number of participants who completed the previous round). 
TABLE 1.   Participant characteristics
Characteristics
Patient panel
(n = 155)
Health  
professional  
panel  
(n = 73)
Surgeon panel
(n = 96)
Sex (female %/male %) 66/34 92/8 31/69
Age, %    
  20–29 y 0 5 1
  30–39 y 6 10 8
  40–49 y 19 28 28
  50–59 y 32 39 31
  60–69 y 30 18 25
  70–79 y 13 0 8
Years in practice, median 
(range)
 20 (1–42) 11 (1–40)
Year since surgery, 
median (range)
3 (1–15)   
Treatment included 
radiotherapy, %
55   
Treatment included 
chemotherapy, %
69   
Temporary stoma, % 86   
Satisfied with bowel 
function, %
   
  Yes 21   
  Sometimes 36   
  No 43   
KEANE ET AL: LARS INTERNATIONAL CONSENSUS DEFINITION280
DISCUSSION
This international patient-provider initiative used robust 
methodology throughout 3 phases to reach a consensus 
definition of LARS. This is the first attempt to define 
LARS that from conception has incorporated multiple 
stakeholders and prioritized patient views. The major 
finding of this consensus definition is that both symptoms 
and consequences are important. The study has identi-
fied 8 symptom complexes and 8 consequences that are 
considered to be of the highest priority when defining 
LARS.
Low anterior resection syndrome has previously been 
pragmatically defined as “disordered bowel function after 
rectal resection, leading to a detriment in quality of life.”8 
This broad definition does not allow the precise measure-
ment of LARS. The LARS score was developed to overcome 
inconsistencies in reporting functional outcome and was 
designed to be a quick clinical evaluation tool to screen 
patients for LARS.12 The LARS score has been widely 
6
7
22
6
8
4
10
7
Patients Healthcare
Professionals
Surgeons Australasia Denmark Spain UK USA
Expert panel attendance Regional attendance
FIGURE 3. Attendance at the final consensus meeting by group and by region.
FIGURE 4. Priorities identified in each phase of the study.
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adopted but appears to suffer from insensitivity to evacu-
atory dysfunction and may overestimate the impact on 
quality of life for some patients.18 Weighting of the LARS 
score response categories makes the LARS score differen-
tially responsive to change in certain dimensions (such as 
urgency) and may mean that more subtle improvements 
on other dimensions are not documented. There is also 
a high rate of LARS in the general population. When the 
LARS score was applied to the Danish population, 19% 
of women and 10% of men aged between 50 and 79 years 
experience symptoms that meet the criteria for major 
LARS.25 This reflects the high sensitivity but low speci-
ficity of the LARS score. The more comprehensive Bowel 
Function Instrument (BFI) developed at Memorial Sloan 
Kettering Cancer Centre was also designed to measure 
bowel dysfunction after sphincter-preserving surgery but 
has not been used widely in the literature.26
The major methodological difference between this 
work and previous attempts to measure LARS is the 
patient-provider approach. Patients were not only par-
ticipants, but also investigators. Active steps were taken 
throughout to ensure that the patient perspective was 
recognized and amplified. This key factor is likely to have 
contributed to a more efficacious definition that accurately 
captures real-world clinical experience. Engagement of the 
wider patient community through advertising the project 
via social media and involvement of patient participants 
active in peer support groups may allow wider dissemina-
tion of the proposed definition.
The overarching difference between the current results 
and the previously published LARS score and BFI is that 
the outcome is a definition not a scoring system. However, 
there is some overlap that is worthy of comment. Both the 
LARS score and BFI enquire about stool frequency, incon-
tinence, urgency, and clustering or fragmentation, which 
is consistent with the proposed definition. The BFI also 
investigates diarrhea or loose stool, soiling, emptying dif-
ficulties (incomplete evacuation), and whether patients 
have to alter their activities because of bowel function, 
which are all concepts that reached consensus in the cur-
rent work. However, the LARS score and the BFI include 
flatus incontinence, which did not reach consensus for in-
clusion in the proposed definition. The BFI also inquires 
about dietary restrictions and distinguishes between daily 
and nocturnal symptoms, which was not borne out in the 
consensus work. The LARS score incorporated quality of 
life by weighting the response categories based on a statis-
tical association with the overall effect of bowel function 
on the quality of life, whereas the BFI simply included a 
question about altering activities because of bowel func-
tion. The consensus work suggests that the impact on 
LARS is such an important component that it is necessary 
to specify the various dimensions that may be impacted by 
the symptoms of LARS.
FIGURE 5. Consensus definition of low anterior resection syndrome. To meet the definition, a patient must have had an anterior resection 
(sphincter-preserving rectal resection) and experience at least 1 of these symptoms that results in at least one of these consequences.
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There are multiple novel components identified in 
this work that may be due to the early and consistent inclu-
sion of the patient perspective. In particular, the concept 
of variable or unpredictable bowel function and altered 
stool consistency may align better with patient experience. 
Patient participants reported that diarrhea was less of an 
issue than unpredictable movements and paste-like con-
sistency that makes evacuation difficult. Clear differenti-
ation into symptoms and consequences is novel. Further 
work is needed to transform the definition presented here 
into a scoring system, but we suggest that inclusion of 
specific patient-centered consequences may allow devel-
opment of a refined tool with greater discrimination of 
changes that occur over time and with treatment.
Our study attempted to obtain a broad range of 
opinion from all important stakeholders across a di-
verse cultural, ethnic, and geographical area, but it was 
limited by the resources available. Ideally, more than 5 
geographical regions could have participated. Strategies 
were used to enhance the patient voice including: pref-
erence to patient panel rankings in the Delphi survey; 
patient consultation meetings were held to allow prox-
ies to take the patient voice to the consensus meeting; 
and visual aids were used to prompt awareness of the 
patient voice during the consensus meeting. However, 
these strategies are not substitutes for the presence of 
patient representatives, and we must acknowledge the 
dominance of the surgical panel at final consensus de-
spite attempts to mitigate this issue. There was a pos-
sibility for sampling bias, in particular, in the patient 
panel, because social media was used extensively in pa-
tient participant recruitment. However, many patient 
participants were active members or even conveners of 
support groups, and they endeavored to present ma-
jority opinions from their wider groups.
The LARS score was designed as a simple tool for clin-
ical evaluation of LARS, and, although developed with ro-
bust methodology, it was not developed on the basis of 
an accepted definition of LARS. This has resulted in the 
LARS score’s inability to capture evacuatory dysfunc-
tion.18 To produce a more robust scoring system, we have 
developed a sequential approach; the initial phase is this 
consensus definition based on broadly agreed upon pri-
orities of LARS, the second will involve transformation of 
these priorities into questions with weighting, and finally 
the new tool will be assessed in both cross-sectional and 
longitudinal validation studies. We have not attempted 
to present a new “LARS score” in this article, merely the 
results of the initial phase. Before moving on to the trans-
formation, we need to assess whether the priorities we 
have presented are acceptable to the wider community. 
We aimed to develop a definition that aligned with the pa-
tient experience so that it will enable greater recognition 
of LARS in routine clinical practice. The production of 
an easily recognizable visual aid will hopefully allow for 
greater awareness of LARS from both patients and clini-
cians, and will hopefully enable more patients to receive 
professional help for their symptoms. We do not expect 
the work presented here to directly improve the assess-
ment of the prevalence of LARS, nor the assessment of 
LARS over time or with treatment, but we will base subse-
quent work toward these aims on the priorities identified 
here.
CONCLUSION
This is the first attempt to define LARS using robust meth-
odology that included multiple stakeholders, particularly 
patients. This novel approach has identified that both 
symptoms and consequences are important priorities in 
LARS. Acknowledging this by transforming these impor-
tant priorities into a new tool to measure LARS may en-
able better identification of rectal cancer survivors who 
experience bowel dysfunction, more accurately assess se-
verity, and enable more precise evaluation of treatment 
approaches for LARS.
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